|
Molbio Diagnostics, a molecular diagnostics solutions company, has announced its investment of USD 30 million in OptraSCAN, a San Jose-based global diagnostics company. This strategic partnership underscores Molbio's commitment to democratising healthcare by making advanced diagnostics accessible to underserved communities and healthcare providers worldwide.
It enables OptraSCAN to accelerate the development and accessibility of digital pathology solutions powered by artificial intelligence. These solutions, which include cloud-based systems for slide scanning, image analysis, and secure data storage, aim to facilitate faster, more accurate diagnoses. This initiative aligns with Molbio's goal of providing advanced diagnostics to every healthcare provider, regardless of location or resource limitations.
"At Molbio Diagnostics, we believe that access to timely and accurate diagnostics should not be a privilege but a right. This strategic alliance with OptraSCAN represents a significant step in our mission to make high-quality, affordable healthcare accessible to all by bringing innovative digital pathology solutions in India and beyond, empowering clinicians with the technology needed to enhance patient care," said Sriram Natarajan, CEO of Molbio Diagnostics.
OptraSCAN's solutions are designed for various healthcare environments, from small laboratories to large medical facilities. With this partnership, OptraSCAN can expand its product portfolio and increase availability, making life-saving diagnostic technology accessible to facilities in rural and under-resourced regions in India.
"OptraSCAN is thrilled to have Molbio Diagnostics as a strategic partner who shares our dedication to innovation and expanding access to quality healthcare. This partnership will allow us to bring life-saving digital pathology solutions to a wider market, helping laboratories of all sizes make timely, precise diagnoses possible. Together with Molbio, we aim to bridge gaps in healthcare by delivering technology that supports high-quality, affordable diagnostics globally," said Abhi Gholap, founder and CEO of OptraSCAN."
In addition to improved access to diagnostic tools, this collaboration will support AI-driven pathology solutions that aim to empower healthcare professionals to diagnose diseases more efficiently, leading to better patient outcomes. The strategic investment will further OptraSCAN's research and development, strengthen its global presence, and bring quality diagnostics to regions historically lacking access to advanced healthcare technology.
Molbio Diagnostics is a global point-of-care diagnostics company. With a commitment to providing rapid, reliable, and robust diagnostic solutions, Molbio brings advanced healthcare technologies to remote areas.
|